Drugs / MDX1201-A488
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02048150 | Mar 2015 → May 2018 | prostate adenocarcinoma | City of Hope Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDX1201-A488 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02048150 ↗ |
| Modality | Monoclonal antibody | “anti-PSMA monoclonal antibody” NCT02048150 ↗ |
| Route | Intravenous | “intravenously administered MDX1201-A488” NCT02048150 ↗ |